Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 9 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Chromocell Therapeutics Corporation | CHRO | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.74 | 07:49:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.74 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 9 | - | 1.21 - 6.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 08:01:35 | 9 | US$ 1.85 | USD |
Chromocell Therapeutics Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 10.04M | 5.77M | - | 0 | -7.38M | -1.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Chromocell Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/09/2024 | 07:30 | GlobeNewswire Inc. | Chromocell Issues Letter to Stockholders from Chief.. |
| 3/21/2024 | 07:30 | GlobeNewswire Inc. | Chromocell Announces Formal Launch of Eye Pain Treatment.. |
| 3/18/2024 | 09:00 | GlobeNewswire Inc. | Chromocell Names Frank Knuettel as Chief Executive Officer,.. |
| 3/11/2024 | 08:00 | GlobeNewswire Inc. | Chromocell to Present at Sidoti Virtual Investor Conference.. |
| 2/27/2024 | 07:00 | GlobeNewswire Inc. | Benuvia Operations, LLC and Chromocell Therapeutics Corp... |
| 2/21/2024 | 15:47 | GlobeNewswire Inc. | Chromocell Therapeutics Announces Closing of Initial Public.. |
| 2/16/2024 | 07:00 | GlobeNewswire Inc. | Chromocell Therapeutics Announces Pricing of Upsized $6.6.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.48 | 1.87 | 1.47 | 1.68 | 11,078 | 0.26 | 17.57% |
| 1 Month | 2.36 | 2.58 | 1.21 | 1.71 | 21,268 | -0.62 | -26.27% |
| 3 Months | 6.00 | 6.00 | 1.21 | 2.97 | 28,945 | -4.26 | -71.00% |
| 6 Months | 6.00 | 6.00 | 1.21 | 2.97 | 28,945 | -4.26 | -71.00% |
| 1 Year | 6.00 | 6.00 | 1.21 | 2.97 | 28,945 | -4.26 | -71.00% |
| 3 Years | 6.00 | 6.00 | 1.21 | 2.97 | 28,945 | -4.26 | -71.00% |
| 5 Years | 6.00 | 6.00 | 1.21 | 2.97 | 28,945 | -4.26 | -71.00% |
Chromocell Therapeutics Description
| Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
